I
1.09
0.03 (2.83%)
| Previous Close | 1.06 |
| Open | 1.04 |
| Volume | 1,036,175 |
| Avg. Volume (3M) | 1,853,100 |
| Market Cap | 49,883,960 |
| Price / Sales | 1.80 |
| Price / Book | 2.88 |
| 52 Weeks Range | |
| Earnings Date | 28 Jul 2025 - 1 Aug 2025 |
| Profit Margin | -194.79% |
| Operating Margin (TTM) | -53.47% |
| Diluted EPS (TTM) | -1.23 |
| Quarterly Revenue Growth (YOY) | -1.10% |
| Total Debt/Equity (MRQ) | 51.46% |
| Current Ratio (MRQ) | 2.32 |
| Operating Cash Flow (TTM) | -7.91 M |
| Levered Free Cash Flow (TTM) | -3.63 M |
| Return on Assets (TTM) | -14.88% |
| Return on Equity (TTM) | -124.75% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | ImmunoPrecise Antibodies Ltd. | Bearish | Bearish |
AIStockmoo Score
1.1
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.13 |
|
ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 5.21% |
| % Held by Institutions | 8.59% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Cibc World Market Inc. | 31 Mar 2025 | 41,200 |
| Thoroughbred Financial Services, Llc | 31 Mar 2025 | 40,000 |
| Gradient Capital Advisors, Llc | 31 Mar 2025 | 26,808 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 5.00 (HC Wainwright & Co., 358.72%) | Buy |
| Median | 4.00 (266.97%) | |
| Low | 3.00 (Benchmark, 175.23%) | Not Rated |
| Average | 4.00 (266.97%) | |
| Total | 1 Buy, 1 Not Rated | |
| Avg. Price @ Call | 0.396 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 11 Apr 2025 | 5.00 (358.72%) | Buy | 0.431 |
| Benchmark | 01 Apr 2025 | 3.00 (175.23%) | Not Rated | 0.361 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 24 Jun 2025 | Announcement | ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology |
| 12 Jun 2025 | Announcement | AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies |
| 05 Jun 2025 | Announcement | ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery |
| 21 May 2025 | Announcement | ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts |
| 20 May 2025 | Announcement | ImmunoPrecise Antibodies (IPA) to Present at Maxim Group’s 2025 Virtual Tech Conference |
| 12 May 2025 | Announcement | IPA’s LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed |
| 11 Apr 2025 | Announcement | ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |